Manmath Patekar

1.6k total citations · 1 hit paper
20 papers, 1.1k citations indexed

About

Manmath Patekar is a scholar working on Immunology, Dermatology and Hematology. According to data from OpenAlex, Manmath Patekar has authored 20 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 9 papers in Dermatology and 9 papers in Hematology. Recurrent topics in Manmath Patekar's work include Psoriasis: Treatment and Pathogenesis (16 papers), Dermatology and Skin Diseases (9 papers) and Autoimmune and Inflammatory Disorders Research (9 papers). Manmath Patekar is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (16 papers), Dermatology and Skin Diseases (9 papers) and Autoimmune and Inflammatory Disorders Research (9 papers). Manmath Patekar collaborates with scholars based in Switzerland, United States and China. Manmath Patekar's co-authors include Arthur Kavanaugh, Shephard Mpofu, Iain B. McInnes, Philip J. Mease, Hanno B. Richards, Christopher T. Ritchlin, Alice B. Gottlieb, R. Landewé, Désirée van der Heijde and Luminita Pricop and has published in prestigious journals such as The Lancet, Journal of Allergy and Clinical Immunology and Annals of the Rheumatic Diseases.

In The Last Decade

Manmath Patekar

19 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

2015 650 citations Iain B. McInnes, Philip J. Mease et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Manmath Patekar Switzerland	10	921	513	396	358	113	20	1.1k
Luke Peterson United States	15	970 1.1×	480 0.9×	294 0.7×	477 1.3×	175 1.5×	59	1.3k
M. Milutinovic Switzerland	7	965 1.0×	197 0.4×	146 0.4×	637 1.8×	217 1.9×	12	1.0k
R. You Switzerland	11	1.2k 1.3×	235 0.5×	174 0.4×	812 2.3×	274 2.4×	17	1.3k
Abby Van Voorhees United States	10	612 0.7×	478 0.9×	87 0.2×	247 0.7×	181 1.6×	25	943
J.M.P.A. van den Reek Netherlands	20	785 0.9×	217 0.4×	75 0.2×	470 1.3×	98 0.9×	41	1.1k
Martina Burlando Italy	16	460 0.5×	252 0.5×	77 0.2×	357 1.0×	227 2.0×	96	859
S. Li United States	8	593 0.6×	118 0.2×	111 0.3×	338 0.9×	91 0.8×	23	683
X. Bordas Spain	17	594 0.6×	176 0.3×	80 0.2×	356 1.0×	133 1.2×	33	934
Rod Kunynetz Canada	9	434 0.5×	249 0.5×	176 0.4×	255 0.7×	69 0.6×	11	661
Ziqian Geng United States	9	706 0.8×	137 0.3×	106 0.3×	552 1.5×	108 1.0×	14	1.1k

Countries citing papers authored by Manmath Patekar

Since Specialization

Citations

This map shows the geographic impact of Manmath Patekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manmath Patekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manmath Patekar more than expected).

Fields of papers citing papers by Manmath Patekar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manmath Patekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manmath Patekar. The network helps show where Manmath Patekar may publish in the future.

Co-authorship network of co-authors of Manmath Patekar

This figure shows the co-authorship network connecting the top 25 collaborators of Manmath Patekar. A scholar is included among the top collaborators of Manmath Patekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manmath Patekar. Manmath Patekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ji, Yan, Claudio Calonder, Eva Hua, et al.. (2023). Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System. Pharmaceutics. 15(9). 2266–2266.

Sticherling, Michael, Arjen Nikkels, Pearl Kwong, et al.. (2023). Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials. American Journal of Clinical Dermatology. 24(5). 821–835. 7 indexed citations

Ensina, Luís Felipe, Jonathan A. Bernstein, Gordon Sussman, et al.. (2023). Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria: Results from the Phase-3 Pivotal Trials. Journal of Allergy and Clinical Immunology. 151(2). AB130–AB130. 5 indexed citations

Magnolo, Nina, Külli Kingo, Vivian Laquer, et al.. (2022). Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study. Pediatric Drugs. 24(4). 377–387. 11 indexed citations

Sigurgeirsson, Bárður, Knut Schäkel, Chih-ho Hong, et al.. (2021). Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. Journal of Dermatological Treatment. 33(3). 1718–1726. 13 indexed citations

Magnolo, Nina, Külli Kingo, Vivian Laquer, et al.. (2021). A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. Journal of the American Academy of Dermatology. 86(1). 122–130. 28 indexed citations

Cai, Lin, Jianzhong Zhang, Min Zheng, Shifa Zhang, & Manmath Patekar. (2021). Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis. Chinese Medical Journal. 134(21). 2629–2631. 3 indexed citations

Sigurgeirsson, Bárður, John Browning, Stephen K. Tyring, et al.. (2021). 27599 Secukinumab administration by a 2 mL autoinjector demonstrates high efficacy with comparable safety and tolerability in adult patients with plaque psoriasis: 16-week results from MATURE. Journal of the American Academy of Dermatology. 85(3). AB154–AB154. 5 indexed citations

Bodemer, Christine, Andrzej Kaszuba, Külli Kingo, et al.. (2021). 25482 Secukinumab efficacy and safety profile in pediatric patients with severe chronic plaque psoriasis up to 1 year. Journal of the American Academy of Dermatology. 85(3). AB59–AB59. 1 indexed citations

10.

Magnolo, Nina, Külli Kingo, Vivian Laquer, et al.. (2021). 26860 Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate-to-severe plaque psoriasis: 52-week results from a randomized trial. Journal of the American Academy of Dermatology. 85(3). AB119–AB119. 2 indexed citations

11.

Sigurgeirsson, Bárður, John Browning, Stephen K. Tyring, et al.. (2021). Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial. Dermatologic Therapy. 35(3). e15285–e15285. 7 indexed citations

12.

Bagel, Jerry, Andrew Blauvelt, John K Nia, et al.. (2020). Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY). Journal of the European Academy of Dermatology and Venereology. 35(1). 135–142. 32 indexed citations

13.

Bodemer, Christine, Andrzej Kaszuba, Külli Kingo, et al.. (2020). Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial. Journal of the European Academy of Dermatology and Venereology. 35(4). 938–947. 60 indexed citations

14.

Elewski, Boni E., John W. Baddley, Atul Deodhar, et al.. (2020). Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis. JAMA Dermatology. 157(1). 43–43. 44 indexed citations

15.

Bruin, Gerard, Hans Hockey, Bárður Sigurgeirsson, et al.. (2019). Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients. British Journal of Clinical Pharmacology. 86(2). 338–351. 20 indexed citations

16.

Bagel, Jerry, John K Nia, Peter W. Hashim, et al.. (2018). Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results). Dermatology and Therapy. 8(4). 571–579. 65 indexed citations

17.

Bissonnette, Robert, Thomas A. Luger, Diamant Thaçi, et al.. (2018). Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). Journal of the European Academy of Dermatology and Venereology. 32(9). 1507–1514. 144 indexed citations

18.

McInnes, Iain B., Philip J. Mease, Bruce Kirkham, et al.. (2015). Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 386(9999). 1137–1146. 650 indexed citations breakdown →

19.

Gottlieb, Alice B., Iain B. McInnes, Philip J. Mease, et al.. (2015). THU0418 Secukinumab Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from the Phase 3 Future 2 Study. Annals of the Rheumatic Diseases. 74. 349–350. 1 indexed citations

20.

Kavanaugh, Arthur, Iain B. McInnes, Stephen Hall, et al.. (2015). THU0411 Secukinumab Efficacy in Anti-TNF-Naive and Anti-TNF-IR Patients with Psoriatic Arthritis: Results of a Phase 3 Multicenter, Double-Blind, Placebo-Controlled Study (Future 2). Annals of the Rheumatic Diseases. 74. 345–346. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact